Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490718 | 0.92 | ALDH1A1 (0.39) | TMEM97SIGMAR1CYP2D6HPGDKDM4E | |
| SCHEMBL6485467 | 0.88 | TMEM97 (0.37) | TMEM97SIGMAR1 | |
| SCHEMBL6496169 | 0.88 | TMEM97 (0.48) | TMEM97SIGMAR1CYP3A4HPGDMEN1 | |
| SCHEMBL6496625 | 0.83 | TMEM97 (0.45) | TMEM97SIGMAR1CYP3A4POLBMEN1 | |
| SCHEMBL6495646 | 0.83 | CYP19A1 (0.38) | TMEM97SIGMAR1CYP3A4CYP2D6POLB | |
| SCHEMBL6498604 | 0.83 | TMEM97 (0.34) | TMEM97SIGMAR1CYP3A4CYP2D6NAMPT | |
| SCHEMBL6495793 | 0.83 | ALDH1A1 (0.41) | SIGMAR1CYP2D6KDM4EMEN1KMT2A | |
| SCHEMBL6494147 | 0.82 | GRM5 (0.35) | TMEM97SIGMAR1CYP3A4MEN1KMT2A | |
| SCHEMBL6495760 | 0.82 | TMEM97 (0.44) | TMEM97SIGMAR1CYP3A4CYP2D6MEN1 | |
| SCHEMBL6488679 | 0.82 | TMEM97 (0.39) | TMEM97SIGMAR1CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | TMEM97 3966/4885SIGMAR1 4243/4885PRMT5 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.